Thrombophilia and pregnancy complications

International Journal of Molecular Sciences

Volumn 16, Issue 12, 2015, Pages 28418-28428

  Simcox, Louise E ^a,b   Ormesher, Laura ^b   Tower, Clare ^a,b   Greer, Ian A ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Fetal growth restriction; Heparin; Pregnancy complications; Recurrent pregnancy loss; Thrombophilia

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ACETYLSALICYLIC ACID; BETA2 GLYCOPROTEIN 1; BLOOD CLOTTING FACTOR 5 LEIDEN; DALTEPARIN; FOLIC ACID; FONDAPARINUX; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; TISSUE PLASMINOGEN ACTIVATOR; ANTICOAGULANT AGENT;

ANTIPHOSPHOLIPID SYNDROME; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; FEMALE; FERTILIZATION IN VITRO; FETAL GROWTH RESTRICTION; GENE MUTATION; HOMOZYGOSITY; HUMAN; HYPERCOAGULABILITY; META ANALYSIS (TOPIC); PLACENTAL ABRUPTION; PREECLAMPSIA; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PROTEIN C DEFICIENCY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT PREGNANCY LOSS; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW (TOPIC); THROMBIN TIME; THROMBOEMBOLISM; THROMBOPHILIA; COMPLICATION; DISEASE MANAGEMENT; GESTATIONAL AGE; IN VITRO FERTILIZATION; NIDATION; PREGNANCY; PREGNANCY COMPLICATIONS;

ANTICOAGULANTS; DISEASE MANAGEMENT; EMBRYO IMPLANTATION; FEMALE; FERTILIZATION IN VITRO; GESTATIONAL AGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; THROMBOPHILIA;

EID: 84949032885     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms161226104     Document Type: Review

References (43)

1. Szecsi, P.B.; Jorgensen, M.; Klajnbard, A.; Andersen, M.R.; Colov, N.P.; Stender, S. Haemostatic reference intervals in pregnancy. Thromb. Haemost. 2010, 103, 718-727. [CrossRef] [PubMed]
2. Sarig, G.; Klil-Drori, A.J.; Chap-Marshak, D.; Brenner, B.; Drugan, A. Activation of coagulation in amniotic fluid during normal human pregnancy. Thromb. Res. 2011, 128, 490-495. [PubMed]
3. McLean, K.C.; Bernstein, I.M.; Brummel-Ziedins, K.E. Tissue factor-dependent thrombin generation across pregnancy. Am. J. Obstet. Gynecol. 2012, 207, e1-e6. [CrossRef] [PubMed]
4. Kamel, H.; Navi, B.B.; Sriram, N.; Hovsepian, D.A.; Devereux, R.B.; Elkind,M.S. Risk of a thrombotic event after the 6-week postpartum period. N. Engl. J. Med. 2014, 370, 1307-1315. [CrossRef] [PubMed]
5. Rodger, M.A.; Carrier, M.; le Gal, G.; Martinelli, I.; Perna, A.; Rey, E.; de Vries, J.I.; Gris, J.C. Low-Molecular-Weight Heparin for Placenta-Mediated Pregnancy Complications Study Group. Meta-analysis of low-molecular-weight heparin to prevent recurrent placenta-mediated pregnancy complications. Blood 2014, 123, 822-828. [CrossRef] [PubMed]
6. Greer, I.A.; Brenner, B.; Gris, J.C. Antithrombotic treatment for pregnancy complications: Which path for the journey to precision medicine? Br. J. Haematol. 2014, 165, 585-599. [CrossRef] [PubMed]
7. Rodger, M.A.; Betancourt, M.T.; Clark, P.; Lindqvist, P.G.; Dizon-Townson, D.; Said, J.; Seligsohn, U.; Carrier, M.; Salomon, O.; Greer, I.A. The association of factor. V Leiden and prothrombin gene mutation and placenta-mediated pregnancy complications: A systematic review and meta-analysis of prospective cohort studies. PLoS Med. 2010, 7, e1000292. [CrossRef] [PubMed]
8. Lykke, J.A.; Bare, L.A.; Olsen, J.; Lagier, R.; Arellano, A.R.; Tong, C.; Paidas, M.J.; Langhoff-Roos, J. Thrombophilias and adverse pregnancy outcomes: Results from the Danish National Birth Cohort. J. Thromb. Haemost. 2012, 10, 1320-1325. [CrossRef] [PubMed]
9. Robertson, L.; Wu, O.; Langhorne, P.; Twaddle, S.; Clark, P.; Lowe, G.D.; Walker, I.D.; Greaves, M.; Brenkel, I.; Regan, L.; et al. Thrombophilia in pregnancy: A systematic review. Br. J. Haematol. 2006, 132, 171-196. [CrossRef] [PubMed]
10. Rodger, M.A.; Walker, M.C.; Smith, G.N.; Wells, P.S.; Ramsay, T.; Langlois, N.J.; Carson, N.; Carrier, M.; Rennicks White, R.; Shachkina, S.; et al. Is thrombophilia associated with placenta-mediated pregnancy complications? A prospective cohort study. J. Thromb. Haemost. 2014, 12, 469-478. [CrossRef] [PubMed]
11. Myers, B.; Pavord, S. Diagnosis and management of antiphospholipid syndrome in pregnancy. Obstet. Gynaecol. 2011, 13, 15-21. [CrossRef]
12. Yetman, D.L.; Kutteh, W.H. Antiphospholipid antibody panels and recurrent pregnancy loss: Prevalence of anticardiolipin antibodies compared with other antiphospholipid antibodies. Fertil. Steril. 1996, 66, 540-546. [PubMed]
13. Opatrny, L.; David, M.; Kahn, S.R.; Shrier, I.; Rey, E. Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: A metaanalysis. J. Rheumatol. 2006, 33, 2214-2221. [PubMed]
14. Abou-Nassar, K.; Carrier, M.; Ramsay, T.; Rodger, M.A. The association between antiphospholipid antibodies and placenta mediated complications: A systematic review and meta-analysis. Thromb. Res. 2011, 128, 77-85. [CrossRef] [PubMed]
15. Nagirnaja, L.; Nommemees, D.; Rull, K.; Christiansen, O.B.; Nielsen, H.S.; Laan, M. Annexin A5 promoter haplotype M2 is not a risk factor for recurrent pregnancy loss in Northern Europe. PLoS ONE 2015, 10, e0131606. [CrossRef] [PubMed]
16. Tiscia, G.; Colaizzo, D.; Chinni, E.; Pisanelli, D.; Scianname, N.; Favuzzi, G.; Margaglione, M.; Grandone, E. Haplotype M2 in the annexin A5 (ANXA5) gene and the occurrence of obstetric complications. Thromb. Haemost. 2009, 102, 309-313. [CrossRef] [PubMed]
17. Bogdanova, N.; Horst, J.; Chlystun, M.; Croucher, P.J.; Nebel, A.; Bohring, A.; Todorova, A.; Schreiber, S.; Gerke, V.; Krawczak, M.; et al. A common haplotype of the annexin A5 (ANXA5) gene promoter is associated with recurrent pregnancy loss. Hum. Mol. Genet. 2007, 16, 573-578. [CrossRef] [PubMed]
18. Ota, S.; Miyamura, H.; Nishizawa, H.; Inagaki, H.; Inagaki, A.; Inuzuka, H.; Suzuki, M.; Miyazaki, J.; Sekiya, T.; Udagawa, Y.; et al. Contribution of fetal ANXA5 gene promoter polymorphisms to the onset of pre-eclampsia. Placenta 2013, 34, 1202-1210. [CrossRef] [PubMed]
19. Pijnenborg, R.; Bland, J.M.; Robertson,W.B.; Brosens, I. Uteroplacental arterial changes related to interstitial trophoblast migration in early human pregnancy. Placenta 1983, 4, 397-413. [CrossRef]
20. An, J.; Waitara, M.S.; Bordas, M.; Arumugam, V.; Hoffmann, R.G.; Petrich, B.G.; Sinha, U.; North, P.E.; Sood, R. Heparin rescues factor V Leiden-associated placental failure independent of anticoagulation in a murine high-risk pregnancy model. Blood 2013, 121, 2127-2134. [CrossRef] [PubMed]
21. Girardi, G.; Redecha, P.; Salmon, J.E. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat. Med. 2004, 10, 1222-1226. [CrossRef] [PubMed]
22. Nelson, S.M.; Greer, I.A. The potential role of heparin in assisted conception. Hum. Reprod. Update 2008, 14, 623-645. [CrossRef] [PubMed]
23. Lessey, B.A. Assessment of endometrial receptivity. Fertil. Steril. 2011, 96, 522-529. [CrossRef] [PubMed]
24. Isermann, B.; Sood, R.; Pawlinski, R.; Zogg, M.; Kalloway, S.; Degen, J.L.; Mackman, N.; Weiler, H. The thrombomodulin-protein C system is essential for the maintenance of pregnancy. Nat. Med. 2003, 9, 331-337. [CrossRef] [PubMed]
25. Qublan, H.; Amarin, Z.; Dabbas, M.; Farraj, A.E.; Beni-Merei, Z.; Al-Akash, H.; Bdoor, A.N.; Nawasreh, M.; Malkawi, S.; Diab, F.; et al. Low-molecular-weight heparin in the treatment of recurrent IVF-ET failure and thrombophilia: A prospective randomized placebo-controlled trial. Hum. Fertil. 2008, 11, 246-253. [CrossRef] [PubMed]
26. Lodigiani, C.; di Micco, P.; Ferrazzi, P.; Libre, L.; Arfuso, V.; Polatti, F.; Benigna, M.; Rossini, R.; Morenghi, E.; Rota, L.; et al. Low-molecular-weight heparin in women with repeated implantation failure. Women's Health 2011, 7, 425-431. [CrossRef] [PubMed]
27. Cohen, H.; O'Brien, P. Disorders of Thrombosis and Hemostasis in Pregnancy, A Guide to Management; Springer-Verlag: London, UK, 2012.
28. Bolton-Maggs, P.H. The management of factor XI deficiency. Haemophil. Off. J. World Fed. Hemophil. 1998, 4, 683-688. [CrossRef]
29. Hanly, J.G.; Gladman, D.D.; Rose, T.H.; Laskin, C.A.; Urowitz, M.B. Lupus pregnancy. A prospective study of placental changes. Arthritis Rheum. 1988, 31, 358-366. [CrossRef] [PubMed]
30. Empson, M.; Lassere, M.; Craig, J.; Scott, J. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst. Rev. 2005, 2. [CrossRef]
31. Kutteh,W.H. Antiphospholipid antibody-associated recurrent pregnancy loss: Treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am. J. Obstet. Gynecol. 1996, 174, 1584-1589. [CrossRef]
32. Rai, R.; Cohen, H.; Dave, M.; Regan, L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997, 314, 253-257. [CrossRef] [PubMed]
33. Farquharson, R.G.; Quenby, S.; Greaves, M. Antiphospholipid syndrome in pregnancy: A randomized, controlled trial of treatment. Obstet. Gynecol. 2002, 100, 408-413. [CrossRef]
34. Backos, M.; Rai, R.; Baxter, N.; Chilcott, I.T.; Cohen, H.; Regan, L. Pregnancy complications in women with recurrent miscarriage associated with antiphospholipid antibodies treated with low dose aspirin and heparin. Br. J. Obstet. Gynaecol. 1999, 106, 102-107. [CrossRef] [PubMed]
35. Demetriou, C.A.S.; White, S.; Peskett, E.; Markoff, A.; Stanier, P.; Moore, G.E.; Regan, L. Investigation of the Annexin A5 M2 haplotype in 500 white European couples who have experienced recurrent spontaneous abortion. Reprod. BioMed. Online 2015, 31, 681-688. [CrossRef] [PubMed]
36. Ueki, H.; Mizushina, T.; Laoharatchatathanin, T.; Terashima, R.; Nishimura, Y.; Rieanrakwong, D.; Yonezawa, T.; Kurusu, S.; Hasegawa, Y.; Brachvogel, B.; et al. Loss of maternal annexin A5 increases the likelihood of placental platelet thrombosis and foetal loss. Sci. Rep. 2012, 2, 827. [CrossRef] [PubMed]
37. Preston, F.E.; Rosendaal, F.R.; Walker, I.D.; Briet, E.; Berntorp, E.; Conard, J.; Fontcuberta, J.; Makris, M.; Mariani, G.; Noteboom, W.; et al. Increased fetal loss in women with heritable thrombophilia. Lancet 1996, 348, 913-916. [CrossRef]
38. Kaandorp, S.P.; Goddijn, M.; van der Post, J.A.; Hutten, B.A.; Verhoeve, H.R.; Hamulyak, K.; Mol, B.W.; Folkeringa, N.; Nahuis, M.; Papatsonis, D.N.M.; et al. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N. Engl. J. Med. 2010, 362, 1586-1596. [CrossRef] [PubMed]
39. Visser, J.; Ulander, V.M.; Helmerhorst, F.M.; Lampinen, K.; Morin-Papunen, L.; Bloemenkamp, K.W.; Kaaja, R.J. Thromboprophylaxis for recurrent miscarriage in women with or without thrombophilia. HABENOX: A randomised multicentre trial. Thromb. Haemost. 2011, 105, 295-301. [CrossRef] [PubMed]
40. Schleussner, E.; Kamin, G.; Seliger, G.; Rogenhofer, N.; Ebner, S.; Toth, B.; Schenk, M.; Henes, M.; Bohlmann, M.K.; Fischer, T.; et al. Low-molecular-weight heparin for women with unexplained recurrent pregnancy loss: A multicenter trial with a minimization randomization scheme. Ann. Intern. Med. 2015, 162, 601-609. [CrossRef] [PubMed]
41. De Vries, J.I.; van Pampus, M.G.; Hague, W.M.; Bezemer, P.D.; Joosten, J.H.; Investigators, F. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: The FRUIT-RCT. J. Thromb. Haemost. 2012, 10, 64-72. [CrossRef] [PubMed]
42. Gris, J.C.; Chauleur, C.; Molinari, N.; Mares, P.; Fabbro-Peray, P.; Quere, I.; Lefrant, J.Y.; Haddad, B.; Dauzat, M. Addition of enoxaparin to aspirin for the secondary prevention of placental vascular complications in women with severe pre-eclampsia. The pilot randomised controlled NOH-PE trial. Thromb. Haemost. 2011, 106, 1053-1061. [CrossRef] [PubMed]
43. Rodger, M.A.; Hague, W.M.; Kingdom, J.; Kahn, S.R.; Karovitch, A.; Sermer, M.; Clement, A.M.; Coat, S.; Chan, W.S.; Said, J.; et al. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): A multinational open-label randomised trial. Lancet 2014, 384, 1673-1683. [CrossRef]